OR WAIT null SECS
October 10, 2019
Following the publication of a statement from the United Kingdom’s Secretary of State for Health and Social Care, Matt Hancock, on the continuity of medicines supply in a ‘no-deal’ Brexit scenario, the UK BioIndustry Association (BIA) has issued a response on Oct. 9, 2019.
Developer of software for drug discovery, Optibrium, has announced in an Oct. 10, 2019 press release the introduction of its Augmented Chemistry services, which incorporate artificial intelligence technologies to help guide drug discovery.
Fujifilm Irvine Scientific has revealed, in an Oct. 8, 2019 press release, that it is has received CE mark approval for key Assisted Reproductive Technologies (ART) products, which are now available in Europe.
October 08, 2019
The new facility raises production capacity by an additional 19,100 m2 and creates 200 new full-time jobs.
October 04, 2019
Data from BIA and Informa Pharma Intelligence have shown that, despite investment slowing across all sectors, the biotech sector of the UK is still managing to raise significant funds.
Glenmark Pharmaceuticals has been granted marketing approval from the Russian Ministry of Healthcare for its film-coated tablets, Montlezir, to treat seasonal and perennial allergic rhinitis.
October 02, 2019
With no plausibly approvable deal on the table in the UK government at the moment, it is possible that Brexit could be extended even further.
A new European Commission is likely, with the support of a new European Parliament, to give a higher profile to healthcare and pharmaceutical matters during its five years in office.
September 27, 2019
T3 Pharmaceuticals, a Swiss company that focuses on immuno-oncology, has announced the closing of its second round of investment financing in which it raised more than CHF 12 million (US$12.1 million).
The European Commission has approved the first plant-derived cannabis-based medicine for the treatment of seizures in patients suffering from two rare, severe forms of childhood-onset epilepsy.